Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19865136 | 0.95 | USP2 (0.47) | USP2HTTLPAR5HSD17B10SPHK1 | |
| SCHEMBL25902360 | 0.91 | USP2 (0.48) | USP2HTTLPAR5HSD17B10SPHK1 | |
| SCHEMBL58458 | 0.90 | USP2 (0.63) | USP2HTTLPAR5HSD17B10TSHR | |
| SCHEMBL25902370 | 0.89 | USP2 (0.47) | USP2HTTLPAR5HSD17B10SPHK1 | |
| SCHEMBL7880864 | 0.87 | USP2 (0.45) | USP2HTTLPAR5HSD17B10TSHR | |
| SCHEMBL24855300 | 0.85 | USP2 (0.53) | USP2HTTLPAR5HSD17B10SPHK1 | |
| Hydrochloric Acid SCHEMBL30274260 | 0.85 | USP2 (0.59) | USP2HTTLPAR5HSD17B10TSHR | |
| SCHEMBL14401173 | 0.84 | USP2 (0.47) | USP2HTTLPAR5HSD17B10SPHK1 | |
| SCHEMBL25904051 | 0.84 | USP2 (0.62) | USP2HTTLPAR5HSD17B10SPHK1 | |
| SCHEMBL25902363 | 0.84 | USP2 (0.52) | USP2HTTLPAR5HSD17B10SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2437791-B1 | POTENTIATION OF AUTOIMMUNE AND INFLAMMATORY DISEASE TREATMENTS BY IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) ANTAGONISTS OF TLR7 AND TLR9 | IDERA PHARMACEUTICALS INC (US) | 2017-03-22 | — | — | EP | claimed |
| US-9243050-B2 | Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8 | Idera Pharamaceuticals, Inc. (US) | 2016-01-26 | — | — | US | claimed |
| US-9206430-B2 | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | IDERA PHARMACEUTICALS, INC. (US) | 2015-12-08 | — | — | US | claimed |
| EP-2021008-B1 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 | IDERA PHARMACEUTICALS INC (US) | 2015-12-02 | — | — | EP | claimed |
| EP-2343307-B1 | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | IDERA PHARMACEUTICALS (US) | 2015-08-05 | — | — | EP | claimed |
| US-8987221-B2 | Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (IRO) antagonists of TLR7 and TLR9 | IDERA PHARMACEUTICALS, INC. (US) | 2015-03-24 | — | — | US | claimed |
| US-20140308300-A1 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 | NOVAQUEST CO-INVESTMENT FUND XV, L.P. | 2014-10-16 | — | — | US | claimed |
| US-8853177-B2 | Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto | IDERA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | claimed |
| US-8853375-B2 | Toll like receptor modulators | IDERA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | claimed |
| US-8759310-B2 | Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8 | IDERA PHARMACEUTICALS, INC. (US) | 2014-06-24 | — | — | US | claimed |
| US-8377898-B2 | Antisense oligonucleotides for prevention and/or treatment of infection, asthma, skin, inflammatory and/or autoimmune disorders | IDERA PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | claimed |
| US-8357665-B2 | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | IDERA PHARMACEUTICALS, INC. (US) | 2013-01-22 | — | — | US | claimed |
| EP-2179061-B1 | TOLL LIKE RECEPTOR MODULATORS | IDERA PHARMACEUTICALS INC (US) | 2012-10-03 | — | — | EP | claimed |
| EP-2451974-A2 | OLIGONUCLEOTIDE-BASED COMPOUNDS AS INHIBITORS OF TOLL-LIKE RECEPTORS | Idera Pharmaceuticals, Inc. (US) | 2012-05-16 | — | — | EP | claimed |
| US-8106173-B2 | Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8 | IDERA PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | claimed |
| EP-2343307-A1 | Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response | Idera Pharmaceuticals (US) | 2011-07-13 | — | — | EP | claimed |
| WO-2011005942-A2 | OLIGONUCLEOTIDE-BASED COMPOUNDS AS INHIBITORS OF TOLL-LIKE RECEPTORS | IDERA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | claimed |
| US-20110009477-A1 | OLIGONUCLEOTIDE-BASED COMPOUNDS AS INHIBITORS OF TOLL-LIKE RECEPTORS | IDERA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | claimed |
| US-20090053148-A1 | TOLL LIKE RECEPTOR MODULATORS | IDERA PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | claimed |
| US-20080171712-A1 | At least two oligonucleotides having modified purine bases, such as deazaguanosines or deaza-adenosines, linked by an alkyl or phenolic diol or triol; vaccines, DNA vaccines; anticarcinogenic, antiallergenic, antiinflammatory agents; bronchodilators | IDERA PHARMACEUTICALS, INC. | 2008-07-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009477-A1 | OLIGONUCLEOTIDE-BASED COMPOUNDS AS INHIBITORS OF TOLL-LIKE RECEPTORS | TLR3, TLR9, TLR1 | USP2 3882/4885HTT 4116/4885LPAR5 89/4885 |
| US-20080171712-A1 | At least two oligonucleotides having modified purine bases, such as deazaguanosines or deaza-adenosines, linked by an alkyl or phenolic diol or triol; vaccines, DNA vaccines; anticarcinogenic, antiallergenic, antiinflammatory agents; bronchodilators | TLR8, TLR7, TLR9 | USP2 1312/4885HTT 2832/4885LPAR5 160/4885 |
| US-20140308300-A1 | STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 | TLR8, TLR7, TLR9 | USP2 3480/4885HTT 1970/4885LPAR5 584/4885 |
| US-20090053148-A1 | TOLL LIKE RECEPTOR MODULATORS | TLR9, TLR3, TLR5 | USP2 4561/4885HTT 4213/4885LPAR5 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.